Family Planning for People with Multiple Sclerosis in Saudi Arabia: an Expert Consensus.
Journal
Multiple sclerosis international
ISSN: 2090-2654
Titre abrégé: Mult Scler Int
Pays: Egypt
ID NLM: 101566861
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
10
2020
accepted:
01
02
2021
entrez:
25
2
2021
pubmed:
26
2
2021
medline:
26
2
2021
Statut:
epublish
Résumé
More than half of all patients with multiple sclerosis (MS) in the Kingdom of Saudi Arabia (KSA) are women of childbearing age. Raising a family is an important life goal for women in our region of the world. However, fears and misconceptions about the clinical course of relapsing-remitting MS (RRMS) and the effects of disease-modifying drugs (DMDs) on the foetus have led many women to reduce their expectations of raising a family, sometimes even to the point of avoiding pregnancy altogether. The increase in the number of DMDs available to manage RRMS and recent studies on their effects in pregnancy have broadened management options for these women. Interferon beta now has an indication in Europe for use during pregnancy (according to clinical need) and can be used during breastfeeding. Glatiramer acetate is a further possible option for women with lower levels of RRMS disease activity who are, or about to become, pregnant; natalizumab may be used up to 30 weeks in patients with higher levels of disease activity. Where possible, physicians need to support and encourage women to pursue their dream of a fulfilling family life, supported where necessary by active interventions for RRMS that are increasingly evidence based.
Identifiants
pubmed: 33628508
doi: 10.1155/2021/6667006
pmc: PMC7899766
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
6667006Informations de copyright
Copyright © 2021 Mohammed Al Jumah et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Breastfeed Med. 2012 Apr;7(2):123-5
pubmed: 21988602
Neurol Ther. 2015 Dec;4(2):93-104
pubmed: 26662361
JAMA Neurol. 2014 Jul 1;71(7):891-5
pubmed: 24821217
J Neurosci Nurs. 2002 Jun;34(3):145-57
pubmed: 12080870
Neurology. 2020 May 5;94(18):e1939-e1949
pubmed: 32284359
Mult Scler. 2016 May;22(6):810-6
pubmed: 26754804
Cells. 2019 Jan 07;8(1):
pubmed: 30621015
Int J Health Sci (Qassim). 2010 Jan;4(1):11-21
pubmed: 21475521
Neurol Ther. 2019 Jun;8(1):13-23
pubmed: 30875021
Neurology. 2018 Oct 23;91(17):e1559-e1569
pubmed: 30266889
J Hum Lact. 2015 May;31(2):233-6
pubmed: 25586712
Int J Community Based Nurs Midwifery. 2020 Jan;8(1):2-11
pubmed: 32039275
Mult Scler. 2011 Apr;17(4):423-30
pubmed: 21220368
Neurol Ther. 2020 Jun;9(1):11-23
pubmed: 32056129
Int J MS Care. 2018 Jan-Feb;20(1):9-14
pubmed: 29507538
Reprod Toxicol. 2020 Aug;95:45-50
pubmed: 32407881
Neurosciences (Riyadh). 2019 Jul;24(3):168-175
pubmed: 31380815
Neurol Ther. 2014 Nov 20;3(2):133-8
pubmed: 26000229
Health Care Women Int. 2011 Feb;32(2):134-9
pubmed: 21229428
Neurol Ther. 2020 Jun;9(1):55-66
pubmed: 32297127
Continuum (Minneap Minn). 2019 Jun;25(3):773-792
pubmed: 31162316
BMC Neurol. 2016 Aug 24;16(1):150
pubmed: 27552976
Neurology. 2018 Mar 6;90(10):e823-e831
pubmed: 29438046
Neurol Ther. 2019 Dec;8(2):241-250
pubmed: 31677060
J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):844-850
pubmed: 29618493
Mult Scler. 2020 Jun;26(7):829-836
pubmed: 30968734
Mult Scler Relat Disord. 2020 Feb;38:101483
pubmed: 31734621
Pract Neurol. 2019 Apr;19(2):106-114
pubmed: 30612100
N Engl J Med. 1998 Jul 30;339(5):285-91
pubmed: 9682040
Mult Scler. 2003 Aug;9(4):342-8
pubmed: 12926838
Ther Adv Neurol Disord. 2019 Mar 28;12:1756286419836913
pubmed: 30944586
Mult Scler. 2016 May;22(6):801-9
pubmed: 26920382
Mult Scler. 2018 Oct;24(12):1627-1634
pubmed: 28857686
Mult Scler. 2015 Feb;21(2):198-205
pubmed: 25159275
BMC Neurol. 2020 Feb 8;20(1):49
pubmed: 32035478